<DOC>
	<DOCNO>NCT00860067</DOCNO>
	<brief_summary>The objective study show quadrivalent live attenuate influenza vaccine ( Q/LAIV ; MEDI3250 ) produce antibody level similar produce commercial vaccine , FluMist .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity Quadrivalent LAIV Adults 18 49 Years Age</brief_title>
	<detailed_description>This randomize , double-blind , active control , multicenter study enrol 1,800 subject 18 49 year age . Subjects randomize site 4:1:1 fashion receive single dose Q/LAIV , trivalent FluMist contain influenza B strain Yamagata lineage ( FluMist/B/Yamagata ) , trivalent FluMist contain influenza B strain Victoria lineage ( FluMist/B/Victoria ) . The study conduct multiple site USA influenza off-season .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 49 year , inclusive , day randomization ( reach eighteenth year birthday yet reach 50th year birthday ) time dose blind investigational product Written inform consent locally require authorization obtain subject prior performing protocolrelated procedure , include screen evaluation Females childbearing potential , ( ie , unless surgically sterile [ eg , bilateral tubal ligation , bilateral oophorectomy , hysterectomy ] , sterile male partner , least 1 year postmenopausal , practice abstinence ) must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) 30 day prior first dose investigational product , must agree continue use precaution 60 day dose investigational product . In addition , subject must also negative urine blood pregnancy test screening , screen Day 0 occur day , day vaccination prior randomization . Investigator judgment require assess female subject 's capability pregnancy . Healthy medical history physical examination OR presence stable underlie chronic medical condition hospitalization require previous year Able complete followup period 180 day post dose vaccine require protocol Subject available telephone Able understand comply requirement protocol , judge investigator Acute illness evidence significant active infection randomization Fever ≥ 100.4°F ( 38°C ) randomization History asthma Any drug therapy 15 day prior randomization expect drug therapy 30 day post dose exception contraceptive chronic medication well tolerate initiate and/or dosage change within 90 day randomization . Previous medical history evidence intercurrent illness might compromise safety subject study Current expect receipt immunosuppressive medication ( inhaled topical corticosteroid permit ) include corticosteroid ( ≥ 20 mg/day prednisone equivalent give daily alternate day ≥ 14 day ) within 30day window around dose investigational product Note : topical corticosteroid uncomplicated dermatitis permit accord judgment investigator ; topical calcineurin inhibitor permit accordance package insert entry study participation . Receipt immunoglobulin blood product within 90 day randomization study expect receipt study participation Receipt investigational drug therapy standard vaccine within 30 day dose investigational product study 30 day dose investigational product ( use license agent indication list package insert permit ) Any know immunosuppressive condition immune deficiency disease include know suspected infection human immunodeficiency virus ( HIV ) History allergic disease reaction likely exacerbate component investigational product include allergy egg , egg protein , gentamicin , gelatin ; serious , life threatening , severe reaction previous influenza vaccination History GuillainBarré syndrome Use antiviral agent activity influenza virus ( include amantadine , rimantadine , oseltamivir zanamivir ) within 30 day prior dose investigational product anticipate use within 30 day vaccination Known suspect mitochondrial encephalomyopathy Lactating woman History alcohol drug abuse , opinion investigator , would affect subject 's safety compliance study Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Employees clinical study site individual involve conduct study , immediate family member individual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>influenza , FluMist , adult , vaccine</keyword>
</DOC>